Britain’s GSK forecast growth in 2022 after racking up 1.4 billion pounds ($1.9 billion) in COVID-related sales in 2021, beating quarterly forecasts in the company’s first earnings report since rejecting Unilever’s bid for GlaxoSmithKline’s consumer arm.

Sanofi still expects the French drugmaker’s COVID-19 vaccine to complete a phase 3 trial in first-quarter 2022 and reported a rise in fourth-quarter 2021 sales and earnings on Feb. 4.

Britain’s GlaxoSmithKline will receive $1.25 billion from Gilead Sciences as part of a settlement between GSK’s HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute.

Galvani Bioelectronics, a clinical-stage company formed through a strategic partnership between GlaxoSmithKline and Verily Life Sciences in 2016 with the aim to develop targeted neuromodulation therapies, announced that the first patient with rheumatoid arthritis was treated through stimulation of the splenic nerve using the its novel bioelectronics platform.

TScan Therapeutics secured clearance from the U.S. Food and Drug Administration for the company’s investigational new drug application to assess TSC-100 in treating patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation (HCT).


GlaxoSmithKline and U.S. partner Vir Biotechnology will boost production of their antibody-based COVID-19 treatment by adding a second manufacturing plant to help meet soaring demand in the United States.

After a rejection from GlaxoSmithKline on a proposed £50 billion (about $68 billion) buyout of GSK’s consumer healthcare business, Unilever announced that the global consumer product giant will not increase its bid.

Hal Barron, who guided the reinvigoration of the pharmaceutical direction at GlaxoSmithKline, is departing the company as GSK undergoes a planned demerger later during 2022.

GlaxoSmithKline declined all three of Unilever’s offers to acquire GSK’s consumer healthcare business, saying the proposal undervalued the division’s present and further worth. 

GSK and Vir Biotechnology said on January 13 they are seeking an expansion to the U.S. approval of their antibody-based COVID-19 treatment to include an option for the therapy to be given as a shot in the arm.